Allspring Global Investments Holdings LLC Sells 175,757 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Allspring Global Investments Holdings LLC trimmed its position in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 46.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 202,851 shares of the medical instruments supplier's stock after selling 175,757 shares during the period. Allspring Global Investments Holdings LLC owned 0.27% of OraSure Technologies worth $866,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of OSUR. Creative Planning bought a new position in shares of OraSure Technologies during the third quarter valued at $54,000. SG Americas Securities LLC acquired a new position in OraSure Technologies during the 1st quarter worth about $72,000. Mackenzie Financial Corp bought a new stake in shares of OraSure Technologies in the 2nd quarter valued at about $72,000. Tocqueville Asset Management L.P. increased its stake in shares of OraSure Technologies by 20.0% in the first quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier's stock valued at $93,000 after buying an additional 2,512 shares during the period. Finally, Shikiar Asset Management Inc. bought a new position in shares of OraSure Technologies during the second quarter worth about $96,000. Institutional investors and hedge funds own 93.50% of the company's stock.

Wall Street Analysts Forecast Growth

OSUR has been the topic of several analyst reports. StockNews.com upgraded OraSure Technologies from a "hold" rating to a "buy" rating in a report on Friday, October 4th. Evercore ISI upped their price objective on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an "in-line" rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, OraSure Technologies has an average rating of "Moderate Buy" and a consensus price target of $6.67.

OraSure Technologies Trading Up 2.6 %

NASDAQ OSUR traded up $0.10 during trading hours on Friday, hitting $4.17. 440,339 shares of the company's stock were exchanged, compared to its average volume of 899,398. The firm has a market cap of $310.96 million, a price-to-earnings ratio of 11.58 and a beta of 0.05. The stock has a 50-day simple moving average of $4.23 and a 200 day simple moving average of $4.49. OraSure Technologies, Inc. has a 1-year low of $3.91 and a 1-year high of $8.45.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.03 EPS for the quarter. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $53.35 million. On average, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.11 earnings per share for the current fiscal year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.